36 Drugs Facing Patent Expirations and Generic Entry in 2022 - 2023

Generic name: tiotropium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 04, 2022
Generic Entry Controlled by: Patent 7,988,001

SPIRIVA RESPIMAT is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug.

This drug has one hundred and sixty-nine patent family members in forty-four countries.

See drug price trends for SPIRIVA RESPIMAT.

The generic ingredient in SPIRIVA RESPIMAT is tiotropium bromide. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the tiotropium bromide profile page.

Generic name: cholic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

CHOLBAM is a drug marketed by Travere.

This drug has one hundred and sixty-nine patent family members in forty-four countries.

See drug price trends for CHOLBAM.

The generic ingredient in CHOLBAM is cholic acid. There are forty-four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cholic acid profile page.

Generic name: lacosamide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2022
Generic Entry Controlled by: Patent RE38551

VIMPAT is a drug marketed by Ucb Inc. There is one patent protecting this drug and three Paragraph IV challenges. Twelve tentatively approved generics are ready to enter the market.

This drug has twenty-two patent family members in eleven countries. There has been litigation on patents covering VIMPAT

See drug price trends for VIMPAT.

The generic ingredient in VIMPAT is lacosamide. There are twenty-two drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the lacosamide profile page.

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 27, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

JATENZO is a drug marketed by Clarus. There are five patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has twenty-four patent family members in nine countries.

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

Generic name: tiotropium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2022
Generic Entry Controlled by: Patent RE38912

SPIRIVA is a drug marketed by Boehringer Ingelheim. There are sixteen patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred patent family members in fifty-two countries. There has been litigation on patents covering SPIRIVA

See drug price trends for SPIRIVA.

The generic ingredient in SPIRIVA is tiotropium bromide. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the tiotropium bromide profile page.

Generic name: goserelin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 13, 2022
Generic Entry Controlled by: Patent 4,100,274

ZOLADEX is a drug marketed by Tersera. There are three patents protecting this drug.

This drug has fifty patent family members in thirty-three countries.

See drug price trends for ZOLADEX.

The generic ingredient in ZOLADEX is goserelin acetate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the goserelin acetate profile page.

Generic name: brimonidine tartrate; timolol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 19, 2022
Generic Entry Controlled by: Patent 7,320,976

COMBIGAN is a drug marketed by Allergan. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has twenty-six patent family members in nineteen countries. There has been litigation on patents covering COMBIGAN

See drug price trends for COMBIGAN.

The generic ingredient in COMBIGAN is brimonidine tartrate; timolol maleate. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the brimonidine tartrate; timolol maleate profile page.

Generic name: fentanyl hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 19, 2022
Generic Entry Controlled by: Patent 6,881,208

IONSYS is a drug marketed by The Medicines Co. There are nine patents protecting this drug.

This drug has one hundred and twenty-two patent family members in thirty countries.

The generic ingredient in IONSYS is fentanyl hydrochloride. There are thirty-one drug master file entries for this API. Additional details are available on the fentanyl hydrochloride profile page.

Generic name: halobetasol propionate; tazarotene
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 25, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

DUOBRII is a drug marketed by Bausch. There are four patents protecting this drug.

This drug has forty-one patent family members in twenty-one countries. There has been litigation on patents covering DUOBRII

See drug price trends for DUOBRII.

The generic ingredient in DUOBRII is halobetasol propionate; tazarotene. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the halobetasol propionate; tazarotene profile page.

Generic name: dalteparin sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 16, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

FRAGMIN is a drug marketed by Pfizer.

This drug has forty-one patent family members in twenty-one countries.

See drug price trends for FRAGMIN.

The generic ingredient in FRAGMIN is dalteparin sodium. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dalteparin sodium profile page.

Generic name: pemetrexed disodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2022
Generic Entry Controlled by: Patent 5,344,932

ALIMTA is a drug marketed by Lilly. There is one patent protecting this drug and four Paragraph IV challenges. Five tentatively approved generics are ready to enter the market.

This drug has eighteen patent family members in eleven countries. There has been litigation on patents covering ALIMTA

See drug price trends for ALIMTA.

The generic ingredient in ALIMTA is pemetrexed disodium. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pemetrexed disodium profile page.

Generic name: aspirin; omeprazole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 31, 2022
Generic Entry Controlled by: Patent 9,364,439

YOSPRALA is a drug marketed by Genus Lifesciences. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in twenty-three countries. There has been litigation on patents covering YOSPRALA

See drug price trends for YOSPRALA.

The generic ingredient in YOSPRALA is aspirin; omeprazole. There are twenty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the aspirin; omeprazole profile page.

Generic name: crofelemer
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 02, 2022
Generic Entry Controlled by: Patent 7,341,744

MYTESI is a drug marketed by Napo Pharms Inc. There are three patents protecting this drug.

This drug has forty-five patent family members in twenty-five countries.

See drug price trends for MYTESI.

The generic ingredient in MYTESI is crofelemer. One supplier is listed for this generic product. Additional details are available on the crofelemer profile page.

Generic name: hydrogen peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 08, 2022
Generic Entry Controlled by: Patent 7,381,427

ESKATA is a drug marketed by Aclaris. There are six patents protecting this drug.

This drug has thirty-one patent family members in eighteen countries.

The generic ingredient in ESKATA is hydrogen peroxide. There are fifty-three drug master file entries for this API. Additional details are available on the hydrogen peroxide profile page.

Generic name: fospropofol disodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 01, 2022
Generic Entry Controlled by: Patent 6,204,257

LUSEDRA is a drug marketed by Eisai Inc. There is one patent protecting this drug.

This drug has thirty-four patent family members in twenty-five countries.

The generic ingredient in LUSEDRA is fospropofol disodium. Additional details are available on the fospropofol disodium profile page.

Generic name: benzyl alcohol
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 11, 2022
Generic Entry Controlled by: Patent 6,793,931

ULESFIA is a drug marketed by Shionogi Inc. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering ULESFIA

The generic ingredient in ULESFIA is benzyl alcohol. There are fifty drug master file entries for this API. Additional details are available on the benzyl alcohol profile page.

Generic name: gadobutrol
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

GADAVIST is a drug marketed by Bayer Hlthcare. There is one patent protecting this drug.

This drug has twenty-five patent family members in sixteen countries.

See drug price trends for GADAVIST.

The generic ingredient in GADAVIST is gadobutrol. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the gadobutrol profile page.

Generic name: gefitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

IRESSA is a drug marketed by Astrazeneca.

This drug has twenty-five patent family members in sixteen countries.

See drug price trends for IRESSA.

The generic ingredient in IRESSA is gefitinib. There are twelve drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the gefitinib profile page.

Generic name: pralatrexate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 16, 2022
Generic Entry Controlled by: Patent 6,028,071

FOLOTYN is a drug marketed by Acrotech. There are three patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in twenty-three countries. There has been litigation on patents covering FOLOTYN

See drug price trends for FOLOTYN.

The generic ingredient in FOLOTYN is pralatrexate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pralatrexate profile page.

Generic name: ixabepilone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 23, 2022
Generic Entry Controlled by: Patent 6,670,384

IXEMPRA KIT is a drug marketed by R-pharm Us Llc. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirteen patent family members in forty-five countries.

See drug price trends for IXEMPRA KIT.

The generic ingredient in IXEMPRA KIT is ixabepilone. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ixabepilone profile page.

Generic name: flibanserin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2022
Generic Entry Controlled by: Patent 7,420,057

ADDYI is a drug marketed by Sprout Pharms. There are four patents protecting this drug.

This drug has eighty-two patent family members in thirty-one countries.

See drug price trends for ADDYI.

The generic ingredient in ADDYI is flibanserin. One supplier is listed for this generic product. Additional details are available on the flibanserin profile page.

Generic name: dichlorphenamide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 07, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

KEVEYIS is a drug marketed by Strongbridge Us.

This drug has eighty-two patent family members in thirty-one countries.

See drug price trends for KEVEYIS.

The generic ingredient in KEVEYIS is dichlorphenamide. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dichlorphenamide profile page.

Generic name: formoterol fumarate; mometasone furoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

DULERA is a drug marketed by Organon.

This drug has eighty-two patent family members in thirty-one countries.

See drug price trends for DULERA.

The generic ingredient in DULERA is formoterol fumarate; mometasone furoate. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the formoterol fumarate; mometasone furoate profile page.

Generic name: sincalide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 16, 2022
Generic Entry Controlled by: Patent 6,803,046

KINEVAC is a drug marketed by Bracco. There is one patent protecting this drug.

This drug has ten patent family members in eight countries. There has been litigation on patents covering KINEVAC

See drug price trends for KINEVAC.

The generic ingredient in KINEVAC is sincalide. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the sincalide profile page.

Generic name: miconazole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 11, 2022
Generic Entry Controlled by: Patent 6,916,485

ORAVIG is a drug marketed by Galt Pharms. There are three patents protecting this drug.

This drug has twenty-four patent family members in fourteen countries.

See drug price trends for ORAVIG.

The generic ingredient in ORAVIG is miconazole. There are twenty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the miconazole profile page.

Generic name: trabectedin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 23, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug.

This drug has forty-four patent family members in thirty-six countries.

See drug price trends for YONDELIS.

The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.

Generic name: fluocinolone acetonide; hydroquinone; tretinoin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 25, 2022
Generic Entry Controlled by: Patent 8,653,053

TRI-LUMA is a drug marketed by Galderma Labs Lp. There are four patents protecting this drug.

This drug has twenty-nine patent family members in eighteen countries.

See drug price trends for TRI-LUMA.

The generic ingredient in TRI-LUMA is fluocinolone acetonide; hydroquinone; tretinoin. There are twelve drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the fluocinolone acetonide; hydroquinone; tretinoin profile page.

Generic name: sulfur hexafluoride lipid-type a microspheres
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

LUMASON is a drug marketed by Bracco. There are two patents protecting this drug.

This drug has nine patent family members in nine countries.

See drug price trends for LUMASON.

The generic ingredient in LUMASON is sulfur hexafluoride lipid-type a microspheres. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the sulfur hexafluoride lipid-type a microspheres profile page.

Generic name: acyclovir; hydrocortisone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2022
Generic Entry Controlled by: Patent 7,223,387

XERESE is a drug marketed by Bausch. There is one patent protecting this drug.

This drug has twenty-five patent family members in twenty-one countries.

See drug price trends for XERESE.

The generic ingredient in XERESE is acyclovir; hydrocortisone. There are fifty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the acyclovir; hydrocortisone profile page.

Generic name: radium ra-223 dichloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2022
Generic Entry Controlled by: Patent 6,635,234

XOFIGO is a drug marketed by Bayer Hlthcare. There is one patent protecting this drug.

This drug has thirty-four patent family members in twenty-one countries.

See drug price trends for XOFIGO.

The generic ingredient in XOFIGO is radium ra-223 dichloride. One supplier is listed for this generic product. Additional details are available on the radium ra-223 dichloride profile page.

Generic name: cocaine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 14, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

GOPRELTO is a drug marketed by Genus Lifesciences. There are eleven patents protecting this drug. There has been litigation on patents covering GOPRELTO

The generic ingredient in GOPRELTO is cocaine hydrochloride. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cocaine hydrochloride profile page.

Generic name: angiotensin ii acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

GIAPREZA is a drug marketed by La Jolla Pharma. There are nine patents protecting this drug.

This drug has twenty-eight patent family members in twenty countries.

See drug price trends for GIAPREZA.

The generic ingredient in GIAPREZA is angiotensin ii acetate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the angiotensin ii acetate profile page.

Generic name: cocaine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2023
Generic Entry Controlled by: FDA Regulatory Exclusivity

NUMBRINO is a drug marketed by Cody Labs Inc.

This drug has twenty-eight patent family members in twenty countries.

See drug price trends for NUMBRINO.

The generic ingredient in NUMBRINO is cocaine hydrochloride. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cocaine hydrochloride profile page.

Generic name: acetaminophen; ibuprofen
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2023
Generic Entry Controlled by: FDA Regulatory Exclusivity

ADVIL DUAL ACTION WITH ACETAMINOPHEN is a drug marketed by Glaxosmithkline.

This drug has twenty-eight patent family members in twenty countries.

The generic ingredient in ADVIL DUAL ACTION WITH ACETAMINOPHEN is acetaminophen; ibuprofen. There are sixty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the acetaminophen; ibuprofen profile page.

Generic name: magnesium chloride; sodium bicarbonate; sodium chloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 04, 2023
Generic Entry Controlled by: Patent 7,300,674

NORMOCARB HF 25 is a drug marketed by Dialysis Sups. There is one patent protecting this drug.

This drug has four patent family members in four countries.

The generic ingredient in NORMOCARB HF 25 is magnesium chloride; sodium bicarbonate; sodium chloride. There are one hundred and forty-six drug master file entries for this API. Additional details are available on the magnesium chloride; sodium bicarbonate; sodium chloride profile page.

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2023
Generic Entry Controlled by: Patent 7,241,065

CHLORAPREP ONE-STEP is a drug marketed by Becton Dickinson Co. There are two patents protecting this drug.

This drug has twelve patent family members in eleven countries.

The generic ingredient in CHLORAPREP ONE-STEP is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.